FrancophonIA/ELRC3.0 huggingface dataset:
English: Losartan therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also section 5.3 ).
Maltese: L-espożizzjoni għat-terapija b'losartan waqt it-tieni u t-tielet trimestri hi magħrufa li tinduċi tossiċità fil-fetu uman (tnaqqis fil-funzjoni tal-kliewi, oligoħidramnios, dewmien għal ossifikazzjoni tal-kranju) u tossiċità lit-tarbija għadha titwieled (insuffiċjenza renali, pressjoni baxxa, iperkalemja) (ara wkoll
English: Add 200 ml of solvent to the 240 ml amber polyethylene terephthalate (PET) bottle provided.
Maltese: Preparazzjoni tas-suspensjoni orali ta' COZAAR [għal 200 ml ta' suspensjoni ta' 2.5 mg/ml]: Żid 200 ml ta' soluzzjoni mal-240 ml flixkun ta' polyethylene terephthalate (PET) ambra fornut.
English: Losartan is not recommended in children with glomerular filtration rate < 30 ml/ min/1.73 m2as no data are available (see section 4.2).
Maltese: Mhux rakkomandat fi tfal b'rata ta' filtrazzjoni glomerulari < 30 ml / min / 1.73 m2, peress li l-ebda tagħrif mhu disponibbli (ara wkoll sezzjoni 4.4).
English: Gastrointestinal disorders: not known: diarrhoea
Maltese: Disturbi gastrointestinali: mhux magħruf: dijarea
English: Patients with proteinuria and a serum creatinine of 1.3 - 3.0 mg/dl were randomised to receive Losartan 50 mg once a day, titrated if necessary, to achieve blood pressure response, or to placebo, on a background of conventional antihypertensive therapy excluding ACE-inhibitors and angiotensin II antagonists.
Maltese: Pazjenti bi protejnurja u b'livelli ta' 1.3 - 3.0 mg/dl ta' kreatinina fis-serum kienu randomizzati biex jirċievu Losartan 50 mg darba kuljum, b'mod iddożat jekk meħtieġ, sabiex jintlaħaq rispons għal pressjoni tad-demm, jew għal plaċebo, fi sfond ta' terapija ta' kontra l-pressjoni konvenzjonali li teskludi impedituri ACE u antagonisti ta' angiotensin II.
English: -Losartan is also not recommended in children with hepatic impairment (see also section 4.4).
Maltese: Losartan huwa wkoll mhux rakkomandat fi tfal b'indeboliment epatiku (ara wkoll sezzjoni 4.4).
English: Box 581, 2003 PC Haarlem The Netherlands
Maltese: Waarderweg 39, 2031 BN Haarlem P.O. Box 581, 2003 PC Haarlem L-Olanda
English: Both biliary and urinary excretions contribute to the elimination of losartan and its metabolites.
Maltese: Kemm l-eliminazzjoni biljari u dik urinarja jikkontribwixxu għall-eliminazzjoni ta' losartan u l-metabolit tiegħu.
English: The antihypertensive effect of losartan was established in a clinical study involving 177 hypertensive pediatric patients 6 to 16 years of age with a body weight > 20 kg and a glomerular filtration rate > 30 ml/ min/ 1.73 m2.
Maltese: Losartan mhux rakkomandat fi tfal li r-rata ta' filtrazzjoni glomerulari tagħhom hi ta' < 30 ml/min/1.73 m2 peress li l-ebda tagħrif mhu disponibbli.
English: affects 1 to 10 users in 1000
Maltese: jaffettwa minn utent 1 sa 10 f'kull 1,000
English: The pharmacokinetic parameters for the metabolite differed to a greater extent between the age groups.
Maltese: Il-parametri farmakokinetiċi tal-metabolit inbiddlu ferm aktar bejn l-istess gruppi ta' età.
English: Losartan slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.
Maltese: Losartan inaqqas il-funzjoni tal-kliewi f'pazjenti li għandhom pressjoni għolja u dijabete ta' tip 2.
English: In controlled clinical studies, once-daily administration of Losartan to patients with mild to moderate essential hypertension produced statistically significant reductions in systolic and diastolic blood pressure.
Maltese: Fi studji kliniċi b'kontrolli, l-għoti darba kuljum ta' Losartan lil pazjenti bi pressjoni essenzjali għolja minn ħafifa sa moderata ikkaġunat tnaqqis statistikament sinifikanti fil-pressjoni tad-demm sistolika u dijastolika.
English: The use of losartan is not recommended in patients with severe hepatic impairment (see section "Do not take losartan").
Maltese: L-użu ta' losartan mhux rakkomandat f'pazjenti li għandhom indeboliment epatiku sever (ara sezzjoni “Tużax losartan”).
English: - In some patients the dose may later be increased to 100 mg losartan (40 ml of COZAAR suspension) once daily.
Maltese: F'xi pazjenti d-doża tista' tiġi miżjuda aktar 'il quddiem għal 100 mg losartan (40 ml ta' suspensjoni ta' COZAAR ) darba kuljum.
English: Use in children and adolescents (6 to 16 years old)
Maltese: Użu fi tfal u adoloxxenti (minn 6 sa 16-il sena)
English: There is no sufficient therapeutic experience with losartan in patients with heart failure and concomitant severe renal impairment, in patients with severe heart failure (NYHA class IV) as well as in patients with heart failure and symptomatic life-threatening cardiac arrhythmias.
Maltese: Hemm esperjenza terapewtika ristretta b'losartan f'pazjenti b'insuffiċjenza kardijaka flimkien ma' indeboliment renali sever f'pazjenti b'insuffiċjenza kardijaka severa (NYHA klassi IV) kif ukoll f'pazjenti b'insuffiċjenza kardijaka u b'arritmiji kardijaċi sintomatiċi li huma ta' theddida għal ħajja.
English: The concomitant use of potassium sparing diuretics, potassium supplements and potassium containing salt substitutes with losartan is not recommended (see section 4.5).
Maltese: L-użu konġunt ta' dijuretiċi li ma jinkoraġixxux it-teħid ta' potassju, supplimenti ta' potassju u sostituti ta' mluħa li fihom il-potassju ma' losartan mhumiex rakkomandati (ara sezzjoni 4.5).
English: The recommended starting dose in patients >20 to <50 kg is 0.7 mg/kg once daily (up to 25 mg total, in exceptional cases where target doses above 25 mg are required, the maximal dose is 50 mg).
Maltese: Id-doża rakkomanadata tal-bidu f'pazjenti ta' >20 sa <50 kg hi ta' 0.7 mg/kg darba kuljum (sa total ta' 25 mg total, f'każijiet eċċezzjonali fejn dożi bersalljati ta' fuq 25 mg kienu meħtieġa, bid-doża massima tkun 50 mg).
English: Member State Marketing Authorisation Holder Invented name Losartan potassium
Maltese: Isem Ivvintat losartan potassium
English: • One foil sachet filled with powder equal to 500 mg losartan potassium
Maltese: • Qartas wieħed ta' fojl b'500 mg ta' trab ta' losartan potassium
English: Limited pharmacokinetic data are available in hypertensive children above one month of age (see section 5.2).
Maltese: Tagħrif farmakokinetiku limitat huwa disponibbli għal tfal bi pressjoni għolja li għandhom aktar minn xahar (ara sezzjoni 5.2:).
English: Overall, there was a dose-response.
Maltese: Globalment, kien hemm rispons għad-doża.
English: The observation of the ELITE Study, that, compared with captopril, Losartan reduced the mortality risk, was not confirmed in the subsequent ELITE II Study, which is described in the following.
Maltese: L-osservazzjoni tal-Istudju ELITE, li, mqabbel ma' captopril, Losartan naqqas ir-riskju ta' mortalità, ma ġiex ikkonfermat fl-Istudju sussegwenti ELITE II, li hu deskritt hawn isfel.
English: 240ml doses)
Maltese: 20ml (10 dożI)
English: RP*>-1 (Relative potency by a mice potency test compared to a reference vaccine that was shown efficacious in sheep)
Maltese: RP*>-1 Qawwa Relattiva skont test ta' qawwa fil-ġrieden imqabbel ma' tilqima ta' referenza li ntweriet li hija effikaċi fin-nagħaġ.
English: Pharma ceutical Form
Maltese: Għamla Farmaċewtika
English: Route of administration
Maltese: Metodu ta' Amministraz zjoni
English: Type I glass vials with chlorobutyl stopper and aluminium seal
Maltese: Virus Bluetongue inattivat, serotip 1, strejn BTV1/ALG2006/01 E1 RP* ≥ 1
English: Withdrawal period
Maltese: Suspension for injection
English: Further information on Extavia can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/extavia.
Maltese: ema.europa.eu/medicines/human/EPAR/extavia.
English: Other information about Extavia
Maltese: Informazzjoni oħra dwar Extavia
English: Extavia received a marketing authorisation valid throughout the EU on 20 May 2008.
Maltese: Extavia ngħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fl-20 ta' Mejju 2008.
English: Extavia contains the active substance interferon beta-1b.
Maltese: Extavia fih is-sustanza attiva interferon beta-1b.
English: Extavia is a medicine used to treat adults who have multiple sclerosis (MS).
Maltese: Extavia huwa mediċina li tintuża biex tikkura adulti li jkollhom sklerożi multipla (MS).
English: The most frequent side effects with Extavia are flu-like symptoms (including fever, chills, joint pain, malaise [feeling unwell], sweating, headache and muscle pain) and reactions at the site of injection.
Maltese: L-effetti sekondarji l-aktar frekwenti b'Extavia huma sintomi li jixbhu l-influwenza (inkluż deni, sirda, uġigħ fil-ġogi, telqa [tħossok ma tiflaħx], għaraq, uġigħ ta' ras u wġigħ fil-muskoli) u reazzjonijiet fis-sit tal-injezzjoni.
English: In both studies, Extavia showed a reduction in the number (30%) of clinical relapses.
Maltese: Fiż-żewġ studji, Extavia wera tnaqqis fl-għadd (30 %) ta' rikaduti kliniċi.
English: Treatment should start with 62.5 micrograms (a quarter of the dose) every other day, increasing progressively over 19 days to reach the recommended dose of 250 micrograms given every other day.
Maltese: Il-kura għandha tibda b'62.5 mikrogrammi (kwart tad-doża) jum iva u jum le, u għandha tiżdied progressivament tul 19-il jum biex tintlaħaq id-doża rakkomandata ta' 250 mikrogramma mogħtija jum iva u jum le.
English: The active substance in Extavia is the protein interferon beta-1b, one of a group of interferons that can be naturally produced by the body to help it fight against viruses and other attacks.
Maltese: Is-sustanza attiva f'Extavia hija l-proteina interferon beta-1b, waħda minn grupp ta' interferons li tista' tiġi prodotta b'mod naturali mill-ġisem biex tgħinu fil-ġlieda kontra l-viruses u attakki oħra.
English: In MS, the immune system (the body's natural defences) malfunctions and attacks parts of the central nervous system (the brain, spinal cord and optic nerve [nerve that sends signals from the eye to the brain]), causing inflammation that damages the nerves and the insulation around them.
Maltese: F'MS, issistema immunitarja (id-difiżi naturali tal-ġisem) ma taħdimx tajjeb u tattakka partijiet tas-sistema nervuża ċentrali (il-moħħ, l-ispina dorsali u n-nerv ottiku [nerv li jibgħat sinjali mill-għajn għall-moħħ]), u tikkawża infjammazzjoni li tagħmel ħsara lin-nervituri u l-iżolament madwarhom.
English: Extavia has also been studied in 1,657 patients in two studies involving secondary progressive MS patients who were able to walk, where it was compared with placebo.
Maltese: Extavia ġie studjat ukoll f'1,657 pazjent f'żewġ studji li kienu jinvolvu pazjenti b'MS progressiva sekondarja li kienu kapaċi jimxu, fejn tqabbel mal-plaċebo.
English: One of the two studies showed a significant delay in the time to disability progression (31% risk reduction due to Extavia) and in the time to becoming wheelchair bound (39%).
Maltese: Wieħed miż-żewġ studji wera dewmien sinifikanti fiż-żmien meta saret il-progressjoni tad-diżabilità (tnaqqis tar-riskju ta' 31 % minħabba Extavia) u fiż-żmien biex jintuża bilfors is-siġġu tar-roti (39 %).
English: In a study involving 487 patients with a single demyelinating event, treatment with Extavia for two years was shown to reduce the risk of developing clinically defined MS: 28% of the patients who received Extavia developed MS, compared with 45% of those who received placebo.
Maltese: MS klinikament definita: 28 % tal-pazjenti li rċevew Extavia żviluppaw MS, meta mqabbla ma' 45 % ta' dawk li rċevew plaċebo.
English: Extavia is available as a powder and solvent that are made up into a solution that supplies a dose of 250 micrograms.
Maltese: Extavia jiġi bħala trab u solvent li jitħalltu f'soluzzjoni li tissupplixxi doża ta' 250 mikrogramma.
English: Extavia was more effective than placebo in reducing the number of annual relapses: patients receiving the medicine had on average 0.84 relapses a year, when patients on placebo had 1.27 relapses.
Maltese: Extavia kien iktar effettiv mill-plaċebo fit-tnaqqis tal-għadd ta' rikaduti annwali: il-pazjenti li kienu qed jingħataw ilmediċina kellhom medja ta' 0.84 rikaduta fis-sena, mentri l-pazjenti fuq plaċebo kellhom 1.27 rikaduta.
English: What are the risks associated with Extavia?
Maltese: X'inhuma r-riskji assoċjati ma' Extavia?
English: As for all medicines, data on the use of Extavia are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Extavia hija ssorveljata kontinwament.
English: Extavia was studied over a two-year period in 338 patients with relapsing remitting MS who were able to walk unaided, where its effectiveness was compared with placebo (a dummy treatment).
Maltese: Extavia ġie studjat fuq perjodu ta' sentejn fi 338 pazjent b'MS b'rikaduti u remissjonijiet li kienu kapaċi jimxu mingħajr għajnuna, fejn l-effettività tiegħu tqabblet ma' plaċebo (kura finta).
English: The exact way that Extavia works in MS is not yet known but the active substance, interferon beta-1b, seems to calm down the immune system, and prevents relapses of MS.
Maltese: Il-mod eżatt kif Extravia jaħdem f'MS għadu mhux magħruf iżda s-sustanza attiva, l-interferon beta-1b, tidher li tikkalma s-sistema immunitarja, u tipprevjeni r-rikaduti ta' MS.
English: • who have MS of the type known as ‘relapsing-remitting', when the patient has attacks (relapses) between periods with no symptoms (remissions), and with at least two relapses within the last two years;
Maltese: • li jkollhom MS tat-tip magħruf bħala “rikaduta-remissjoni”, meta l-pazjent ikollu attakki (rikaduti) bejn perjodi mingħajr sintomi (remissjonijiet), u b'tal-anqas żewġ rikaduti fl-aħħar sentejn;
English: How is Extavia used?
Maltese: Kif jaħdem Extavia?
English: • who have secondary progressive MS (the type of MS that comes after relapsing-remitting MS), when their disease is active.
Maltese: • li jkollhom MS progressiva sekondarja (it-tip ta' MS li tiġi wara
English: What measures are being taken to ensure the safe and effective use of Extavia?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Extavia?
English: For the full list of side effects and restrictions with Extavia, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet b'Extavia, ara l-fuljett ta' tagħrif.
English: • who have experienced the signs of MS for the first time, and these are severe enough to justify treatment with injected corticosteroids (anti-inflammatory medicines).
Maltese: • li esperjenzaw is-sinjali ta' MS għall-ewwel darba, u dawn huma severi biżżejjed biex jiġġustifikaw il-kura b'kortikosterojdi injettati (mediċini antiinfjammatorji).
English: MS is a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves.
Maltese: MS hija marda li fiha l-infjammazzjoni tagħmel ħsara lill-iżolament ta' protezzjoni madwar in-nervituri (demyelination) kif ukoll lin-nervituri nfushom.
English: − familial mediterranean fever (FMF);
Maltese: − deni familjali tal-mediterran (FMF);
English: The full EPAR for Ilaris can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This summary was last updated in 03-2017.
Maltese: Is-sommarju ġie aġġornat l-aħħar fi 03-2017.
English: Gouty arthritis
Maltese: Artrite Gotta
English: − hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD);
Maltese: − sindromu iperimmunoglobulina D (HIDS)/defiċjenza tal-mevalonat kinażi (MKD) (mevalonate kinase deficiency);
English: As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 22 March 2017
Maltese: Peress li l-kumpanija pprovdiet l-informazzjoni addizzjonali mitluba, iċ-‘ċirkostanzi ta' eċċezzjoni' tneħħew fil- fis-22 ta' Marzu 2017.
English: Ilaris canakinumab
Maltese: Ilaris kanakinumab
English: The response rates with Ilaris and placebo were 46% and 8%, respectively in patients with TRAPS, 35% and 6% in patients with HIDS/MKD, and 61% and 6% in patients with FMF.
Maltese: Ir-rati ta' rispons b'Ilaris u l-plaċebo kienu 46% u 8%, rispettivament f'pazjenti bi TRAPS, 35% u 6% f'pazjenti b'HIDS/MKD, u 61% u 6% f'pazjenti b'FMF.
English: Other information about Ilaris
Maltese: Informazzjoni oħra dwar Ilaris
English: This is a summary of the European public assessment report (EPAR) for Ilaris.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Ilaris.
English: Why is Ilaris approved?
Maltese: Għaliex ġie approvat Ilaris?
English: The risk of developing a new gouty arthritis attack was also reduced with Ilaris (17% with Ilaris versus 37% with triamcinolone acetonide).
Maltese: Ir-riskju li jiżviluppa attakk ġdid ta' artrite gotta wkoll tnaqqas b'Ilaris (17% b'Ilaris kontra s-37% bl-aċetonida trijamċinolina).
English: Ilaris contains the active substance canakinumab.
Maltese: Ilaris fih is-sustanza attiva kanakinumab.
English: Two studies involving 454 patients with gouty arthritis showed that Ilaris was more effective than another anti-inflammatory medicine triamcinolone acetonide at reducing pain.
Maltese: Żewġ studji li involvew 454 pazjent bl-artrite gotta wrew li Ilaris kien aktar effettiv minn mediċina antiinfjammatorja oħra aċetonida trijamċinolina fit-tnaqqis tal-uġigħ.
English: The active substance in Ilaris, canakinumab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a messenger molecule or ‘cytokine' in the body called interleukin-1 beta.
Maltese: Is-sustanza attiva f'Ilaris, il-kanakinumab, hija antikorp monoklonali, tip ta' proteina li tfassal biex jagħraf u jeħel ma' molekula messaġġiera jew 'ċitokina' fil-ġisem imsejħa interleukin-1 beta.
English: − cryopyrin-associated periodic syndromes (CAPS);
Maltese: − sindromi perjodiċi assoċjati mal-kriopirin (CAPS);
English: Because of the similarities between childhood Still's disease and the adult form (adult-onset Still's disease, AOSD), Ilaris is expected to have similar benefits in adults.
Maltese: Minħabba s-similaritajiet bejn il-forma tal-marda ta' Still fit-tfulija u dik fl-adulti (il-marda ta' Still li tibda fil-ħajja adulta, AOSD), Ilaris huwa mistenni li jkollu benefiċċji simili fl-adulti.
English: • 4 types of periodic fever syndromes (diseases marked by recurring inflammation and fever) in adults and children aged 2 and above:
Maltese: • 4 tipi ta' sindromi perjodiċi tad-deni (mard li jiġi minn infjammazzjoni u deni ripetuti) f'adulti u tfal minn sentejn 'il fuq:
English: A study in 84 patients with childhood Still's disease (also known as systemic juvenile idiopathic arthritis, SJIA) found that Ilaris was more effective than placebo at reducing symptoms of arthritis: around 84% of patients who received Ilaris achieved the required reduction in symptoms, compared with about 10% of patients who received placebo.
Maltese: Studju f'84 pazjent bil-marda ta' Still fit-tfulija (magħrufa wkoll bħala artrite idjopatika ġovanili sistematika, SJIA) sab li Ilaris kien aktar effettiv minn plaċebo fit-tnaqqis tas-sintomi tal-artrite: madwar 84% tal-pazjenti li ħadu Ilaris kisbu t-tnaqqis meħtieġ fis-sintomi, meta mqabbla ma' madwar 10% tal-pazjenti li ħadu plaċebo.
English: Serious infections have been observed in patients taking Ilaris.
Maltese: Ġew osservati infezzjonijiet serji fil-pazjenti li ngħataw Ilaris.
English: In a second study in childhood Still's disease (177 patients), the risk of experiencing a disease flare was reduced by 64% with Ilaris, compared with placebo.
Maltese: Fit-tieni studju fil-marda ta' Still fit-tfulija (177 pazjent), ir-riskju li lmarda terġa' tfeġġ tnaqqas b'64% b'Ilaris, meta mqabbel mal-plaċebo.
English: Ilaris was originally authorised under ‘exceptional circumstances', because, for scientific reasons, limited information was available at the time of approval.
Maltese: Ilaris oriġinarjament kien awtorizzat taħt "ċirkostanzi ta' eċċezzjoni", għax, għal raġunijiet xjentifiċi, kien hemm disponibbli informazzjoni limitata fi żmien l-approvazzjoni.
English: • Gouty arthritis, painful inflammation of the joints caused by deposit of urate crystals (in adults).
Maltese: • Artrite gotta, infjammazzjoni bl-uġigħ tal-ġogi kkawżata minn depożiti tal-kristalli tal-urat (fladulti).
English: What are the risks associated with Ilaris?
Maltese: X'inhuma r-riskji assoċjati ma' Ilaris?
English: − tumour necrosis factor receptor associated periodic syndrome (TRAPS);
Maltese: − sindromu perjodiku assoċjat mar-riċettur ta' fattur ta' nekrożi tumorali (TRAPS);
English: In patients taking Ilaris, after 3 days, the pain level was reduced from 74 to 25 (on a standard rating scale from 0 to 100), whereas in patients taking the comparator the pain level was reduced from 74 to 35.
Maltese: Fil-pazjenti li jieħdu Ilaris, wara tlett ijiem, il-livell tal-uġigħ naqas minn 74 għal 25 (fuq skala ta' klassifikazzjoni standard minn 0 sa 100), filwaqt li f'pazjenti li jieħdu l-komparatur il-livell tal-uġigħ tnaqqas minn 74 sa 35.
English: Periodic fever syndromes
Maltese: Sindromi perjodiċi tad-deni
English: By attaching to interleukin-1 beta, canakinumab blocks its activity, helping to reduce inflammation thereby relieving the symptoms of the diseases.
Maltese: Meta teħel mal-interleukin-1 beta, ilkanakinumab timblokka l-attività tiegħu, u tgħin biex titnaqqas l-infjammazzjoni u b'hekk jittaffew issintomi tal-mard.
English: Ilaris is a medicine for treating the following inflammatory conditions:
Maltese: Ilaris huwa mediċina għall-kura tal-kundizzjonijiet infjammatorji li ġejjin:
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ilaris on 23 October 2009.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Ilaris valida fl-Unjoni Ewropea kollha fit-23 ta' Ottubru 2009.
English: Ilaris is given as a single injection under the skin every 8 weeks for CAPs and every 4 weeks for the other periodic fever syndromes (TRAPS, HIDS/MKD and FMF) and Still's disease.
Maltese: Ilaris jingħata bħala injezzjoni waħda taħt il-ġilda kull 8 ġimgħat għal CAPs u kull 4 ġimgħat għassindromi perjodiċi ta' deni l-oħra (TRAPS, HIDS/MKD u FMF) u l-marda ta' Still.
English: Three studies involving 220 adults and children 2 years and older showed that Illaris was effective at reducing relapses of CAPS symptoms after a 24-week treatment period.
Maltese: Ilaris kien effettiv fittnaqqis ta' rikaduti tas-sintomi ta' CAPS wara perjodu ta' 24 ġimgħa ta' kura.
English: Studies have shown that Ilaris is effective at reducing symptoms or relapses in patients with periodic fever syndromes, Still's disease and gouty arthritis.
Maltese: L-istudji wrew li Ilaris kien effettiv fit-tnaqqis ta' sintomi jew rikaduti f'pazjenti b'sindromi perjodiċi taddeni, il-marda ta' Still u l-artrite gotta.
English: A fourth study in 181 patients with other periodic fever syndromes found that Ilaris was more effective than placebo in achieving a response (symptoms resolved with no new flare ups).
Maltese: Ir-raba' studju f'181 pazjent b'sindromi tad-deni perjodiċi oħra sab li Ilaris kien aktar effettiv minn plaċebo fil-ksib ta' rispons (is-sintomi kienu solvuti mingħajr ma reġgħet feġġet il-marda).
English: • Still's disease, a rare disease causing inflammation of joints as well as rash and fever (in adults and children aged 2 and above);
Maltese: • Il-marda ta' Still, marda rari li tikkawża infjammazzjoni fil-ġogi kif ukoll raxx u deni (f'adulti u tfal li għandhom minn sentejn 'il fuq);
English: In the two other CAPS studies, which did not compare Ilaris with any other treatment, 85% of patients on Ilaris had no relapses at all.
Maltese: F'żewġ studji oħra tal-CAPS, li ma qabblux Ilaris ma' kuri oħra, 85% tal-pazjenti fuq Ilaris ma kellhom l-ebda rikaduta.